Lupin receives USFDA nod for Testosterone gel

Pharmaceutical major Lupin said that it has received approval from  the United States Food and Drug Administration for the sales of a generic equivalent of AbbVie Inc’s AndroGel.

Testosterone Gel is used for hormone replacement in men who are not able to produce enough testosterone. The medication is absorbed through the skin, enters the bloodstream, and helps the body reach normal testosterone levels.

Testosterone Gel 1.62% had annual sales of $893 million in the US market as of December 2018.

On Wednesday, Lupin launched a generic equivalent of Alvogen Group Holdings’ psychiatric drug Fluoxetine.

Mumbai-based Lupin is one of the world’s biggest makers of generic drugs, and sells both branded and generic formulations, biotechnology products and pharmaceutical ingredients globally.

It is the world’s biggest manufacturer of anti-TB medicines and focuses on cardiovascular, diabetology, asthma, paediatric, CNS, GI, anti-infective and NSAID segments of the pharma market.